High dose versus low dose fludarabine in the treatment of patients with severe refractory rheumatoid arthritis

Journal of Rheumatology

Volumn 25, Issue 9, 1998, Pages 1694-1704

  Davis Jr , John C ^a,c   Fessler, Barri J ^a   Tassiulas, Ioannis O ^a   McInnes, Iain B ^a   Yarboro, Cheryl H ^a   Pillemer, Stanley ^a   Wilder, Ronald ^a   Fleisher, Thomas A ^b   Klippel, John H ^a   Boumpas, Dimitrios T ^a  

^a NIAMS ^*

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c Division of Rheumatology   (United States)

Author keywords

Fludarabine; Nucleoside analog; Rheumatoid arthritis; Treatment

Indexed keywords

ALKYLATING AGENT; ANTIRHEUMATIC AGENT; AZATHIOPRINE; CHLORAMBUCIL; CYCLOSPORIN; FLUDARABINE; GAMMA INTERFERON; GOLD; HYDROXYCHLOROQUINE; INTERLEUKIN 10; INTERLEUKIN 2; METHOTREXATE; NUCLEOSIDE; PENICILLAMINE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; BODY SURFACE; CLINICAL ARTICLE; DOSE RESPONSE; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN TISSUE; LYMPHOCYTE PROLIFERATION; MALE; PHENOTYPE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ANTIGENS, CD; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; PHENOTYPE; PLATELET COUNT; TIME FACTORS; TREATMENT OUTCOME; VIDARABINE;

EID: 0031728168     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (71)

1. Scott DL, Symmons DPM, Coulton BL, Popert AJ. Long-term outcome of treating rheumatoid arthritis: results after 20 years. Lancet 1987;1:1108-11.
2. Pincus T, Brooks RH, Callahan LF. Prediction of long-term mortality in patients with rheumatoid arthritis according to simple questionnaire and joint count measures. Ann Intern Med 1994;120:26-34.
3. Wolfe F, Mitchell DM, Sibley JT, et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994;37:481-94.
4. Cash JM, Klippel JH. Second-line drug therapy for rheumatoid arthritis. N Engl J Med 1994;330:1368-75.
5. Sigler JW, Bluhm GB, Duncan H, Sharp JT, Ensign DC, McCrum WR. Gold salts in the treatment of rheumatoid arthritis: a double-blind study. Ann Intern Med 1974;80:21-6.
6. The Multicentre Trial Group. Controlled trial of D-penicillamine in severe rheumatoid arthritis. Lancet 1973;1:275-80.
7. Williams HJ, Ward JR, Dahl SL, et al. A controlled trial comparing sulfasalazine, gold sodium thiomalate, and placebo in rheumatoid arthritis. Arthritis Rheum 1988;31:702-13.
8. Hannonen P, Mottonen T, Hakola M, Oka M. Sulfasalazine in early rheumatoid arthritis: a 48-week double-blind, prospective, placebo-controlled study. Arthritis Rheum 1993;36:1501-9.
9. Ward JR, Williams HJ, Egger MJ, et al. Comparison of auranofin, gold sodium thiomalate, and placebo in the treatment of rheumatoid arthritis: a controlled clinical trial. Arthritis Rheum 1983;26: 1303-15.
10. Weinblatt ME, Coblyn JS, Fox DA, et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985;312: 818-22.
11. Willkens RF, Urowitz MB, Stablein DM, et al. Comparison of azathioprine, methotrexate, and the combination of both in the treatment of rheumatoid arthritis: a controlled clinical trial. Arthritis Rheum 1992;35:849-56.
12. Williams HJ, Ward JR, Reading JC, et al. Comparison of auranofin, methotrexate, and the combination of both in the treatment of rheumatoid arthritis: a controlled clinical trial. Arthritis Rheum 1992;35:259-69.
13. Yocum DE, Klippel JH, Wilder RL, et al. Cyclosporin A in severe, treatment-refractory rheumatoid arthritis. A randomized study. Ann Intern Med 1988;109:863-9.
14. Felson DT, Anderson JJ, Meenan RF. Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis: a meta-analysis of published clinical trials. Arthritis Rheum 1992;35:1117-2.
15. Wolfe F, Hawley DJ, Cathey MA. Termination of a slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts. J Rheumatol 1990;17: 994-1002.
16. Weinblatt ME, Kaplan H, German BF, et al. Methotrexate in rheumatoid arthritis: a five-year prospective multicenter study. Arthritis Rheum 1994;37:1492-8.
17. Kremer JM, Phelps CT. Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis: update after a mean of 90 months. Arthritis Rheum 1992;35:138-45.
18. Alarcon GS, Tracy IC, Blackburn WD Jr. Methotrexate in rheumatoid arthritis: toxic effects as the major factor in limiting long-term treatment. Arthritis Rheum 1989;32:671-6.
19. O'Dell JR, Case L. The treatment of rheumatoid arthritis in 1995: results of a survey [abstract]. Arthritis Rheum 1995;38 Suppl 9:S366.
20. Tugwell P, Pincus T, Yocum D, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N Engl J Med 1995;333:137-41.
21. O'Dell JR, Haire CE, Erikson N, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996;334:1287-91.
22. Van der Lubbe PA, Dijkmans BAC, Markusse HM, Nässander U, Breedveld FC. A randomized, double-blind, placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis. Arthritis Rheum 1995;38:1097-106.
23. Moreland LW, Pratt PW, Mayes MD, et al. Double-blind, placebo controlled multicenter trial using chimeric monoclonal anti-CD4 antibody in rheumatoid arthritis patients receiving concomitant methotrexate. Arthritis Rheum 1995;38:1581-8.
24. Weinblatt ME, Maddison PJ, Bulpitt KJ, et al. CAMPATH-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis: An intravenous dose-escalation study. Arthritis Rheum 1995;38:1589-94.
25. Moreland LW, Sewwell KL, Trentham DE, et al. Diphtheria-interleukin-2 fusion protein (DAB486IL-2) in refractory rheumatoid arthritis: a double-blind placebo-controlled trial with open label extension. Arthritis Rheum 1995;38:1177-86.
26. Tak PP, Van der Lubbe PA, Cauli A, et al. Reduction of synovial inflammation after anti-CD4 monoclonal antibody treatment in early rheumatoid arthritis. Arthritis Rheum 1995;38:1457-5.
27. Choy EHS, Pitzalis C, Cauli A, et al. Percentage of anti-CD4 monoclonal antibody-coated lymphocytes in the rheumatoid joints is associated with clinical improvement. Arthritis Rheum 1996;39:52-6.
28. Elliott MJ, Maini RN, Feldmann M, et al. Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis. Lancet 1994;344:1125-7.
29. Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
30. Moreland LW, Baumgartner W, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-7.
31. Tallman MS, Hakimian D. Purine nucleoside analogs: emerging roles in indolent lymphoproliferative disorders. Blood 1995;86:2463-74.
32. Plunkett W, Gandhi V. Nucleoside analogs: cellular pharmacology, mechanisms of action and strategies for combination therapy. In: Cheson BD, Keating MJ, Plunkett W, editors. Nucleoside analogs in cancer therapy. New York: Marcel Dekker, Inc.; 1997.
33. French Cooperative Group on Chronic Lymphocytic Leukemia. Multicenter prospective randomized trial of fludarabine versus cyclophosphamide, doxorubicin and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukemia. Lancet 1996;347:1432-8.
34. Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J, Beutler E. Cladribine in treatment of chronic progressive multiple sclerosis. Lancet 1994;344:9-13.
35. Tassiulas IO, Boumpas DT, Vaughan EM, et al. A pilot study of low-dose fludarabine in membranous nephropathy refractory to therapy [abstract]. J Am Soc Nephrol 1996;7:1782.
36. Fessler BJ, Yarboro CH, Klippel JH, Hama N, Wilder RL, Boumpas DT. A pilot study of fludarabine in refractory rheumatoid arthritis [abstract]. Arthritis Rheum 1995;38 Suppl 9:S282.
37. Smith OP, Hoffbrand AV, Buckley C. Fludarabine and psoriasis. N Engl J Med 1994;330:1540-1.
38. Eibschutz B, Baird SM, Weisman MH, et al. Oral 2-chlorodeoxyadenosine in psoriatic arthritis. Arthritis Rheum 1995;38:1604-9.
39. Davis JC, Klippel J, Boumpas D, Yarboro C, Larsen A, Scott D. 2′ chlorodeoxyadenosine treatment in lupus nephritis [abstract]. Arthritis Rheum 1996;39 Suppl 9:S245.
40. Beutler E, Carson D, Sipe JC, et al. 2-Chlorodeoxyadenosine in nonmalignant disorders. In: Cheson BD, Keating MJ, Plunkett W, editors. Nucleoside analogs in cancer therapy. New York: Marcel Dekker, Inc.; 1997.
41. Tassiulas IO, Davis JC Jr, Fessler BJ, et al. Fludarabine in non-malignant disorders. In: Cheson BD, Keating MJ, Plunkett W, editors. Nucleoside analogs in cancer therapy. New York: Marcel Decker Inc.; 1997.
42. Priebe T, Platsoucas CD, Seki H, Fox FE, Nelson JA. Purine nucleoside modulation of functions of human lymphocytes. Cell Immunol 1990;129:321-8.
43. Conolly K, Roubinian JR, Wofsy D. Development of murine lupus in CD4-depleted NZB/NZW mice sustained inhibition of residual CD4+ T cells is required to suppress autoimmunity. J Immunol 1992;149:3083-9.
44. Arnett F, Edworthy S, Bloch D, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
45. Robertson LE, O'Brien S, Kantarjian H, et al. A 3-day schedule of fludarabine in previously treated chronic lymphocytic leukemia. Leukemia 1995;9:1444-9.
46. Cortes JE, O'Brien SM. Defining the optimal dose schedule of purine analogs and assessment of response. In: Cheson BD, Keating MJ, Plunkett W, editors. Nucleoside analogs in cancer therapy. New York: Marcel Dekker, Inc.; 1997.
47. Mackall C, Fleisher T, Brown M, et al. Thymopoiesis and CD4 T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med 1995;332:143-9.
48. Felson D, Anderson J, Toers M, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
49. Croft M, Bradley LM, Swain SL. Naive versus memory CD4 T cell response to antigen. Memory cells are less dependent on accessory cell costimulation and can respond to many antigen-presenting cell types including resting B cells. J Immunol 1994;152:2675-85.
50. Hakim FT, Cepeda R, Kaimei S, et al. Constraints on CD4 recovery post chemotherapy in adults. Thymic insufficiency and apoptotic decline of expanded peripheral CD4 cells. Blood 1997;90:3789-98.
51. Cheson B. Infections and immunosuppressive complications of purine analogue therapy. J Clin Oncol 1995;13:2431-48.
52. Jendro MC, Ganten T, Matteson EL, Weyand CM, Goronzy JJ. Emergence of oligoclonal T cell populations following therapeutic T cell depletion in rheumatoid arthritis. Arthritis Rheum 1995;38:1242-51.
53. Mackall CL, Hakim FT, Gress RE. T cell regeneration: All repertoires are not created equal. Immunol Today 1997;18:245-51.
54. Ranges GE, Sriram S, Cooper SM. Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4. J Exp Med 1985;162:1105-12.
55. Wofsy D, Seaman WE. Successful treatment of autoimmunity in NZB/NZW F1 mice with monoclonal antibody to L3T4. J Exp Med 1985;161:378-91.
56. Rudmerman EM, Weinblatt ME, Thurmond LM, Pinkus GS, Gravallese EM. Synovial tissue response to treatment with CAMPATH-1H. Arthritis Rheum 1995;38:254-8.
57. Mima T, Saeki Y, Ohshima S, et al. Transfer of rheumatoid arthritis into severe combined immunodeficient mice. The pathogenic implications of T cell populations oligoclonally expanding in the rheumatoid joints. J Clin Invest 1995;96:1746-58.
58. Shiozawa S, Tanaka Y, Fujita T, Tokuhisa T. Destructive arthritis without lymphocyte infiltration in H2-c-fos transgenic mice. J Immunol 1992;148:3100-4.
59. Marchal G, Seman M, Milon G, Truffa-bachi P, Zilberfarb V. Local adoptive transfer of skin delayed-type hypersensitivity initiated by a single T lymphocyte. J Immunol 1982;129:954-8.
60. Firestein GS. Invasive fibroblast-like synoviocytes in rheumatoid arthritis: passive responders or transformed aggressors? Arthritis Rheum 1996;39:1781-90.
61. Moreland LW, Heck LW Jr, Koopman WJ. Biologic agents for treating rheumatoid arthritis: concepts and progress. Arthritis Rheum 1997;40:397-409.
62. Fox DA. The role of T cells in the immunopathogenesis of rheumatoid arthritis: new perspectives. Arthritis Rheum 1997;40:598-609.
63. Arend WP. The pathophysiology and treatment of rheumatoid arthritis. Arthritis Rheum 1997;40:595-7.
64. Levy OR, Weisman M, Wiescenhutter C, et al. Results of a placebo-controlled multicenter trial using a primatized non-depleting, anti-CD4 monoclonal antibody in the treatment of rheumatoid arthritis [abstract]. Arthritis Rheum 1996;39 Suppl:S122.
65. Epstein WV. Expectation bias in rheumatoid arthritis clinical trials. Arthritis Rheum 1996;39:1773-80.
66. Tilley BC, Alarcon GS, Heyse SP, et al. Minocycline in rheumatoid arthritis: a 48-week, double-blind, placebo-controlled trial. Ann Intern Med 1995;122:81-9.
67. Pillemer SR, Fowler SE, Tilley BC, et al. Meaningful improvement criteria sets in a rheumatoid arthritis clinical trial. Arthritis Rheum 1997;40:419-25.
68. Dasgupta B, Robinson C, Corrigal V, Young S, Panayi G. Selective lymphocyte depletion with deoxycoformycin (DCF) induces flare of rheumatoid arthritis [abstract]. Arthritis Rheum 1995;38 Suppl:S280.
69. Massarotti EM, Liu N, Mier J, Atkins MB. Chronic inflammatory arthritis after treatment with high-dose interleukin-2 for malignancy. Am J Med 1992;92:693-7.
70. Giralt S, Estey E, Albitar M, et al. Engraftment of allogenetic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997;89:4531-6.
71. Wicks I, Cooley H, Szer J. Autologous hemopoietic stem cell transplantation. A possible cure for rheumatoid arthritis? Arthritis Rheum 1997;40:1005-11.